Your browser is no longer supported. Please, upgrade your browser.
Settings
ALIM Alimera Sciences, Inc. daily Stock Chart
ALIM [NASD]
Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-0.40 Insider Own1.05% Shs Outstand71.11M Perf Week-4.32%
Market Cap94.58M Forward P/E- EPS next Y-0.08 Insider Trans0.00% Shs Float68.33M Perf Month-5.00%
Income-24.70M PEG- EPS next Q-0.05 Inst Own62.30% Short Float1.08% Perf Quarter-2.21%
Sales36.00M P/S2.63 EPS this Y8.90% Inst Trans-12.92% Short Ratio2.84 Perf Half Y-7.64%
Book/sh-0.72 P/B- EPS next Y61.90% ROA-36.00% Target Price4.00 Perf Year-18.90%
Cash/sh0.38 P/C3.52 EPS next 5Y- ROE55.50% 52W Range1.03 - 1.72 Perf YTD23.15%
Dividend- P/FCF- EPS past 5Y2.60% ROI318.60% 52W High-22.67% Beta2.24
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin92.30% 52W Low29.13% ATR0.05
Employees125 Current Ratio4.60 Sales Q/Q8.30% Oper. Margin-54.10% RSI (14)37.47 Volatility4.55% 3.15%
OptionableYes Debt/Eq- EPS Q/Q72.30% Profit Margin-68.60% Rel Volume0.60 Prev Close1.34
ShortableYes LT Debt/Eq- EarningsAug 02 AMC Payout- Avg Volume258.68K Price1.33
Recom2.00 SMA20-4.04% SMA50-7.72% SMA200-1.77% Volume154,308 Change-0.75%
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Sep-19-17 09:25AM  Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference GlobeNewswire
Sep-12-17 04:01PM  Alimera Sciences Announces ILUVIEN® now available in Ireland GlobeNewswire
Sep-11-17 04:01PM  Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment Conference GlobeNewswire
Sep-08-17 11:16PM  ETFs with exposure to Alimera Sciences, Inc. : September 9, 2017 Capital Cube
Sep-07-17 08:39AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017 Capital Cube
Sep-05-17 07:30AM  Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress GlobeNewswire
Aug-31-17 04:01PM  Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-29-17 04:05PM  Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in France GlobeNewswire
Aug-13-17 02:46AM  Edited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-09-17 07:30AM  Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting GlobeNewswire
Aug-07-17 07:30AM  Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017 GlobeNewswire
Aug-04-17 01:08AM  Alimera Sciences reports 2Q loss Associated Press
Aug-03-17 07:05AM  Investor Network: ALIMERA SCIENCES INC to Host Earnings Call ACCESSWIRE +5.63%
Jul-25-17 04:05PM  Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment GlobeNewswire
Jul-24-17 11:00AM  Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017 GlobeNewswire
Jul-19-17 04:05PM  Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K. GlobeNewswire
Jul-13-17 03:26PM  ETFs with exposure to Alimera Sciences, Inc. : July 13, 2017 Capital Cube
Jul-12-17 09:45AM  Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN® GlobeNewswire +5.63%
09:30AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences Zacks
Jul-11-17 09:26AM  5 Top Multibagger Biotech Stocks to Buy in the 2nd Half Zacks
Jul-10-17 04:56PM  Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis GlobeNewswire
04:01PM  pSivida Out-licenses EMEA Rights for Durasert Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSividas Revenue Generation GlobeNewswire
Jun-29-17 02:50PM  ETFs with exposure to Alimera Sciences, Inc. : June 29, 2017 Capital Cube
Jun-16-17 03:20PM  ETFs with exposure to Alimera Sciences, Inc. : June 16, 2017 Capital Cube
Jun-14-17 09:39AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-02-17 08:15AM  Blog Coverage Eli Lilly's Late-Stage Bladder Cancer Drug CYRAMZA Meets Primary Endpoint Accesswire
May-18-17 11:16AM  Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-12-17 11:55AM  Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-09-17 07:00AM  Investor Network: ALIMERA SCIENCES INC to Host Earnings Call Accesswire +5.52%
May-08-17 06:11PM  Alimera Sciences reports 1Q loss Associated Press -5.23%
04:58PM  Alimera Sciences Reports First Quarter 2017 Financial Results GlobeNewswire
May-03-17 02:42PM  Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017 GlobeNewswire
May-01-17 03:34PM  ETFs with exposure to Alimera Sciences, Inc. : May 1, 2017 Capital Cube
07:30AM  Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO GlobeNewswire
Apr-20-17 02:11PM  ETFs with exposure to Alimera Sciences, Inc. : April 20, 2017 Capital Cube
Apr-07-17 03:44PM  ETFs with exposure to Alimera Sciences, Inc. : April 7, 2017 Capital Cube
Mar-27-17 03:48PM  ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017 Capital Cube
03:48PM  ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017
Mar-20-17 09:02AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
09:02AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:47PM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:47PM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
08:20AM  Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8% Zacks
Mar-13-17 07:30AM  Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain GlobeNewswire +12.77%
Mar-09-17 01:04PM  ALIMERA SCIENCES INC Financials
Mar-07-17 07:30AM  Alimera Sciences to Present at the 29th Annual ROTH Conference GlobeNewswire
Mar-03-17 04:23PM  ALIMERA SCIENCES INC Files SEC form 10-K, Annual Report
10:05AM  Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference GlobeNewswire
Mar-02-17 04:21PM  Edited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT Thomson Reuters StreetEvents
05:03AM  Alimera Sciences reports 4Q loss Associated Press
Mar-01-17 05:08PM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:00PM  Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Alimera Sciences Inc Earnings Release - After Market Close
Feb-23-17 11:24AM  Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017 GlobeNewswire
Feb-22-17 08:00AM  Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada GlobeNewswire
08:00AM  Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada Marketwired
Feb-06-17 09:00AM  Alimera Sciences Announces the Reimbursement of ILUVIEN® in Italy GlobeNewswire
Jan-11-17 12:33PM  ETFs with exposure to Alimera Sciences, Inc. : January 11, 2017
Dec-18-16 11:35AM  Is Alimera Sciences Inc (ALIM) A Good Stock To Buy? at Insider Monkey
Dec-16-16 11:05AM  ETFs with exposure to Alimera Sciences, Inc. : December 16, 2016
Dec-06-16 10:56AM  ETFs with exposure to Alimera Sciences, Inc. : December 6, 2016
Nov-16-16 05:18PM  ALIMERA SCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Nov-14-16 12:49PM  ETFs with exposure to Alimera Sciences, Inc. : November 14, 2016
Nov-04-16 04:10PM  ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report
11:58AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016
Nov-03-16 11:57PM  Edited Transcript of ALIM earnings conference call or presentation 3-Nov-16 2:00pm GMT -5.39%
11:50AM  ETFs with exposure to Alimera Sciences, Inc. : November 3, 2016
09:07AM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
05:07AM  Alimera Sciences reports 3Q loss
Nov-02-16 04:36PM  Alimera Sciences Announces Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q3 2016 Alimera Sciences Inc Earnings Release - After Market Close
Oct-26-16 07:30AM  Alimera Sciences Begins Selling ILUVIEN® in the Middle East GlobeNewswire
Oct-25-16 12:36PM  Alimera Sciences to Report Third Quarter 2016 Financial Results on November 2, 2016 GlobeNewswire
Oct-20-16 05:06PM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O
04:42PM  Alimera Sciences Strengthens Financial Position GlobeNewswire
09:29AM  ETFs with exposure to Alimera Sciences, Inc. : October 20, 2016
Oct-05-16 10:03AM  ETFs with exposure to Alimera Sciences, Inc. : October 5, 2016
Sep-20-16 10:02AM  ETFs with exposure to Alimera Sciences, Inc. : September 20, 2016
Sep-06-16 08:00AM  Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress GlobeNewswire
Aug-23-16 09:00AM  Alimera Sciences Inc (ALIM): Great Point Partners Reveals 5.12% Stake at Insider Monkey
Aug-16-16 04:01PM  Alimera Sciences Announces Exercise of Underwriters Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock GlobeNewswire
Aug-12-16 02:06PM  ETFs with exposure to Alimera Sciences, Inc. : August 12, 2016
Aug-11-16 11:11AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
09:40AM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
08:41AM  Alimera Sciences Prices Public Offering of Common Stock GlobeNewswire
Aug-10-16 04:05PM  ALIMERA SCIENCES INC Files SEC form 8-K, Other Events -6.86%
04:01PM  Alimera Sciences Proposes Public Offering of Common Stock GlobeNewswire
Aug-09-16 07:30AM  Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting GlobeNewswire
Aug-05-16 06:05PM  Edited Transcript of ALIM earnings conference call or presentation 4-Aug-16 2:00pm GMT
05:17PM  ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report
Aug-04-16 06:59AM  Alimera Sciences reports 2Q loss -12.00%
06:07AM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
Aug-03-16 05:41PM  Alimera Sciences Announces Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q2 2016 Alimera Sciences Inc Earnings Release - After Market Close
Jul-31-16 07:04PM  Tempur Sealy (TPX), GrubHub (GRUB), United States Steel Corporation (X) Among Top Weekly Gainers at Insider Monkey
Jul-27-16 09:57AM  Alimera Sciences (ALIM) Shares March Higher, Can It Continue?
Jul-26-16 07:35AM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financ +59.43%
07:30AM  Alimera Sciences Pre-Announces Record Second Quarter 2016 Revenue GlobeNewswire
Jul-22-16 09:04AM  Alimera Sciences (ALIM) Is in Oversold Territory: What's Next?
Jul-20-16 12:08PM  ETFs with exposure to Alimera Sciences, Inc. : July 20, 2016
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myers C. DanielCEOMar 10Sale1.3921,17229,429180,861Mar 13 04:56 PM
Roberts Calvin W.DirectorDec 12Sale1.1150,00055,50065,820Dec 14 04:30 PM
Holland DavidSVP of Sales and MarketingOct 11Option Exercise1.3327,97137,201134,389Oct 13 04:13 PM
Myers C. DanielCEOOct 11Option Exercise1.3355,14773,346145,131Oct 13 04:14 PM
Green KennethSVP & Chief Scientific OfficerOct 11Option Exercise1.3344,20858,797136,561Oct 13 04:13 PM